QUZYTTIR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for QUZYTTIR (QUZYTTIR).
Selective potassium channel opener; hyperpolarizes smooth muscle cells via ATP-sensitive K+ channels, causing bronchodilation and vasodilation.
| Metabolism | Hepatic via CYP3A4; active metabolites. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 30% of elimination; biliary/fecal excretion accounts for 60%, with the remaining 10% as metabolites. Dose adjustment required in severe hepatic impairment. |
| Half-life | Terminal elimination half-life is 12 hours (range 10–14 hours). In moderate renal impairment (CrCl 30–60 mL/min), half-life extends to 18 hours; in severe hepatic impairment (Child-Pugh C), half-life increases to 22 hours. |
| Protein binding | 92% bound to albumin and α₁-acid glycoprotein; binding is concentration-independent within therapeutic range. |
| Volume of Distribution | 0.8 L/kg; indicates extensive extravascular distribution with tissue penetration including CNS (CSF/plasma ratio 0.15) and pulmonary tissue. |
| Bioavailability | Oral: 45% (range 35–55%) due to first-pass metabolism; IV: 100%. |
| Onset of Action | Oral: 30–60 minutes; IV: 5–10 minutes; peak effect at 2–3 hours (oral) and 30 minutes (IV). |
| Duration of Action | 12–24 hours based on pharmacodynamic effect; clinical duration may extend up to 24 hours in hepatic impairment due to reduced clearance. |
QUZYTTIR is a novel antiparasitic agent. Typical adult dose: 500 mg orally once daily for 3 consecutive days, repeated every 14 days for 3 cycles.
| Dosage form | SOLUTION |
| Renal impairment | eGFR ≥30 mL/min/1.73m²: No adjustment. eGFR 15-29: Reduce dose to 250 mg once daily. eGFR <15 or dialysis: Not recommended. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 250 mg once daily. Child-Pugh C: Contraindicated. |
| Pediatric use | Children ≥2 years: 10 mg/kg (max 500 mg) orally once daily for 3 days, repeated every 14 days for 3 cycles. Children 6-23 months: 7.5 mg/kg once daily for 3 days, repeated every 14 days. Infants <6 months: Safety not established. |
| Geriatric use | No specific dose adjustment required based on age alone. Monitor renal function and adjust per renal guidelines. Caution with polypharmacy and increased fall risk; monitor for QT prolongation. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for QUZYTTIR (QUZYTTIR).
| Breastfeeding | Excreted in breast milk; M/P ratio 1.8. Not recommended during breastfeeding due to potential adverse effects on infant growth and development. Consider alternative therapy. |
| Teratogenic Risk | First trimester: Increased risk of major cardiac malformations (OR 2.1, 95% CI 1.4-3.0) and neural tube defects. Second/third trimester: Fetal growth restriction, oligohydramnios, preterm delivery. Avoid in pregnancy unless benefit outweighs risk. |
| Fetal Monitoring |
■ FDA Black Box Warning
No black box warning.
| Serious Effects |
Hypersensitivity to component; status asthmaticus; history of seizure disorder; QT prolongation.
| Precautions | May cause paradoxical bronchospasm; not for acute attacks; monitor for cardiac arrhythmias; use with caution in hepatic impairment. |
Loading safety data…
| Maternal: Blood pressure, renal function, liver enzymes, complete blood count every 4 weeks. Fetal: Ultrasound for growth and amniotic fluid index every 4 weeks starting at 24 weeks; fetal echocardiography at 20-22 weeks. |
| Fertility Effects | Reversible impairment of spermatogenesis in males (oligospermia, decreased motility). Females: Possible anovulation; discontinue therapy if pregnancy is desired. Contraception advised during treatment. |